March 26 (Reuters) - Gene therapy maker bluebird bio

said on Tuesday it plans to restate its financial

statements for 2022 and for each of the first three quarters of

2022 and 2023 following accounting errors.

The company has also identified "material weakness in its

internal control over financial reporting", it said.

The errors related to accounting of certain arrangements

with some contract manufacturing organizations, according to

bluebird.

The company said it will require additional time to prepare

and review its financial statements and other disclosures before

filing its Form 10-K annual report for 2023 with the U.S.

Securities and Exchange Commission.